Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
Janani L, Munro APS, Wright A, Aley PK, Babbage G, Baxter D, Bawa T, Bibi S, Bula M, Cathie K, Chatterjee K, Cosgrove C, Enever Y, Galiza E, Goodman AL, Green CA, Harris M, Hicks A, Jones CE, Kanji N, van der Klaauw AA, Libri V, Llewelyn MJ, Mansfield R, McGregor AC, Minassian AM, Moore P, Mujadidi YF, Belhadef HT, Holliday K, Osanlou O, Osanlou R, Pacurar M, Palfreeman A, Regan K, Saich S, Saralaya D, Sharma S, Sheridan R, Stokes M, Thomson EC, Todd S, Twelves C, Wright D, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Cornelius V, Lambe T, Heath PT, Liu X, Faust SN; COV-BOOST study group.
Janani L, et al. Among authors: bawa t.
J Infect. 2025 Aug 7:106576. doi: 10.1016/j.jinf.2025.106576. Online ahead of print.
J Infect. 2025.
PMID: 40782888
Free article.